Perspectives on the Treatment of Malignant Pleural Mesothelioma
Most mesotheliomas originate in the pleura and are due to asbestos exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality remains high in part because of late diagnosis and treatment resistance. Pemetrexed–cisplatin and immune checkpoint inhibitors modestly extend su...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-09, Vol.385 (13), p.1207-1218 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1218 |
|---|---|
| container_issue | 13 |
| container_start_page | 1207 |
| container_title | The New England journal of medicine |
| container_volume | 385 |
| creator | Janes, Sam M Alrifai, Doraid Fennell, Dean A |
| description | Most mesotheliomas originate in the pleura and are due to asbestos exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality remains high in part because of late diagnosis and treatment resistance. Pemetrexed–cisplatin and immune checkpoint inhibitors modestly extend survival. |
| doi_str_mv | 10.1056/NEJMra1912719 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2575832036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2575832036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-744d6a907aac38d98b7c97b397e979edf475804a9c77e0bc8c8b073e7f24f8053</originalsourceid><addsrcrecordid>eNp10E1Lw0AQBuBFFFurR68SEMFLdDa7m909iZT6Ras91HPYbCaako-6mwj-e1NbBQXnMgw8vAwvIccULiiI-PJx8jBzhmoaSap3yJAKxkLOId4lQ4BIhVxqNiAH3i-hH8r1PhkwLgSNGAzJ1RydX6Fti3f0QVMH7SsGC4emrbBugyYPZqYsXmrTH_MSO2fKYIa-6VlZNJU5JHu5KT0ebfeIPN9MFuO7cPp0ez--noZWALSh5DyLjQZpjGUq0yqVVsuUaYlaasxyLoUCbrSVEiG1yqoUJEOZRzxXINiInG9yV65569C3SVV4i2Vpamw6n0SiD2ARsLinp3_osulc3X_3pbhWCtYq3CjrGu8d5snKFZVxHwmFZN1s8qvZ3p9sU7u0wuxHf1fZg7MNqCqf1Lis_gn6BA_hfbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2575498806</pqid></control><display><type>article</type><title>Perspectives on the Treatment of Malignant Pleural Mesothelioma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Janes, Sam M ; Alrifai, Doraid ; Fennell, Dean A</creator><contributor>Longo, Dan L ; Longo, Dan L.</contributor><creatorcontrib>Janes, Sam M ; Alrifai, Doraid ; Fennell, Dean A ; Longo, Dan L ; Longo, Dan L.</creatorcontrib><description>Most mesotheliomas originate in the pleura and are due to asbestos exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality remains high in part because of late diagnosis and treatment resistance. Pemetrexed–cisplatin and immune checkpoint inhibitors modestly extend survival.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMra1912719</identifier><identifier>PMID: 34551230</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antigens ; Antineoplastic Agents - therapeutic use ; Asbestos ; Biopsy ; Cancer therapies ; Cisplatin ; Clinical trials ; Combined Modality Therapy ; Critical Care ; Critical Care General ; Epigenetic Repression ; Hematology ; Humans ; Immune checkpoint inhibitors ; Immunotherapy ; Inflammation ; Intubation ; Medical prognosis ; Mesothelioma ; Mesothelioma, Malignant - diagnosis ; Mesothelioma, Malignant - pathology ; Mesothelioma, Malignant - therapy ; Oncology ; Patients ; Pleura ; Pleura - diagnostic imaging ; Pleura - pathology ; Pleura - surgery ; Pleural effusion ; Pleural Neoplasms - diagnosis ; Pleural Neoplasms - pathology ; Pleural Neoplasms - therapy ; Pulmonary ; Radiotherapy ; Surgery ; Surgery General ; Treatment resistance ; Treatments in Oncology ; Ultrasonic imaging</subject><ispartof>The New England journal of medicine, 2021-09, Vol.385 (13), p.1207-1218</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-744d6a907aac38d98b7c97b397e979edf475804a9c77e0bc8c8b073e7f24f8053</citedby><cites>FETCH-LOGICAL-c500t-744d6a907aac38d98b7c97b397e979edf475804a9c77e0bc8c8b073e7f24f8053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMra1912719$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2575498806?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,2745,2746,26082,27903,27904,52360,54042,64361,64363,64365,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34551230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Longo, Dan L</contributor><contributor>Longo, Dan L.</contributor><creatorcontrib>Janes, Sam M</creatorcontrib><creatorcontrib>Alrifai, Doraid</creatorcontrib><creatorcontrib>Fennell, Dean A</creatorcontrib><title>Perspectives on the Treatment of Malignant Pleural Mesothelioma</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Most mesotheliomas originate in the pleura and are due to asbestos exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality remains high in part because of late diagnosis and treatment resistance. Pemetrexed–cisplatin and immune checkpoint inhibitors modestly extend survival.</description><subject>Antigens</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Asbestos</subject><subject>Biopsy</subject><subject>Cancer therapies</subject><subject>Cisplatin</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Critical Care</subject><subject>Critical Care General</subject><subject>Epigenetic Repression</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Intubation</subject><subject>Medical prognosis</subject><subject>Mesothelioma</subject><subject>Mesothelioma, Malignant - diagnosis</subject><subject>Mesothelioma, Malignant - pathology</subject><subject>Mesothelioma, Malignant - therapy</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pleura</subject><subject>Pleura - diagnostic imaging</subject><subject>Pleura - pathology</subject><subject>Pleura - surgery</subject><subject>Pleural effusion</subject><subject>Pleural Neoplasms - diagnosis</subject><subject>Pleural Neoplasms - pathology</subject><subject>Pleural Neoplasms - therapy</subject><subject>Pulmonary</subject><subject>Radiotherapy</subject><subject>Surgery</subject><subject>Surgery General</subject><subject>Treatment resistance</subject><subject>Treatments in Oncology</subject><subject>Ultrasonic imaging</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10E1Lw0AQBuBFFFurR68SEMFLdDa7m909iZT6Ras91HPYbCaako-6mwj-e1NbBQXnMgw8vAwvIccULiiI-PJx8jBzhmoaSap3yJAKxkLOId4lQ4BIhVxqNiAH3i-hH8r1PhkwLgSNGAzJ1RydX6Fti3f0QVMH7SsGC4emrbBugyYPZqYsXmrTH_MSO2fKYIa-6VlZNJU5JHu5KT0ebfeIPN9MFuO7cPp0ez--noZWALSh5DyLjQZpjGUq0yqVVsuUaYlaasxyLoUCbrSVEiG1yqoUJEOZRzxXINiInG9yV65569C3SVV4i2Vpamw6n0SiD2ARsLinp3_osulc3X_3pbhWCtYq3CjrGu8d5snKFZVxHwmFZN1s8qvZ3p9sU7u0wuxHf1fZg7MNqCqf1Lis_gn6BA_hfbQ</recordid><startdate>20210923</startdate><enddate>20210923</enddate><creator>Janes, Sam M</creator><creator>Alrifai, Doraid</creator><creator>Fennell, Dean A</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20210923</creationdate><title>Perspectives on the Treatment of Malignant Pleural Mesothelioma</title><author>Janes, Sam M ; Alrifai, Doraid ; Fennell, Dean A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-744d6a907aac38d98b7c97b397e979edf475804a9c77e0bc8c8b073e7f24f8053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Asbestos</topic><topic>Biopsy</topic><topic>Cancer therapies</topic><topic>Cisplatin</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Critical Care</topic><topic>Critical Care General</topic><topic>Epigenetic Repression</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Intubation</topic><topic>Medical prognosis</topic><topic>Mesothelioma</topic><topic>Mesothelioma, Malignant - diagnosis</topic><topic>Mesothelioma, Malignant - pathology</topic><topic>Mesothelioma, Malignant - therapy</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pleura</topic><topic>Pleura - diagnostic imaging</topic><topic>Pleura - pathology</topic><topic>Pleura - surgery</topic><topic>Pleural effusion</topic><topic>Pleural Neoplasms - diagnosis</topic><topic>Pleural Neoplasms - pathology</topic><topic>Pleural Neoplasms - therapy</topic><topic>Pulmonary</topic><topic>Radiotherapy</topic><topic>Surgery</topic><topic>Surgery General</topic><topic>Treatment resistance</topic><topic>Treatments in Oncology</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Janes, Sam M</creatorcontrib><creatorcontrib>Alrifai, Doraid</creatorcontrib><creatorcontrib>Fennell, Dean A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Janes, Sam M</au><au>Alrifai, Doraid</au><au>Fennell, Dean A</au><au>Longo, Dan L</au><au>Longo, Dan L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perspectives on the Treatment of Malignant Pleural Mesothelioma</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-09-23</date><risdate>2021</risdate><volume>385</volume><issue>13</issue><spage>1207</spage><epage>1218</epage><pages>1207-1218</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Most mesotheliomas originate in the pleura and are due to asbestos exposure. The incidence is decreasing somewhat with asbestos remediation, but mortality remains high in part because of late diagnosis and treatment resistance. Pemetrexed–cisplatin and immune checkpoint inhibitors modestly extend survival.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>34551230</pmid><doi>10.1056/NEJMra1912719</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-09, Vol.385 (13), p.1207-1218 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2575832036 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antigens Antineoplastic Agents - therapeutic use Asbestos Biopsy Cancer therapies Cisplatin Clinical trials Combined Modality Therapy Critical Care Critical Care General Epigenetic Repression Hematology Humans Immune checkpoint inhibitors Immunotherapy Inflammation Intubation Medical prognosis Mesothelioma Mesothelioma, Malignant - diagnosis Mesothelioma, Malignant - pathology Mesothelioma, Malignant - therapy Oncology Patients Pleura Pleura - diagnostic imaging Pleura - pathology Pleura - surgery Pleural effusion Pleural Neoplasms - diagnosis Pleural Neoplasms - pathology Pleural Neoplasms - therapy Pulmonary Radiotherapy Surgery Surgery General Treatment resistance Treatments in Oncology Ultrasonic imaging |
| title | Perspectives on the Treatment of Malignant Pleural Mesothelioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T21%3A04%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perspectives%20on%20the%20Treatment%20of%20Malignant%20Pleural%20Mesothelioma&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Janes,%20Sam%20M&rft.date=2021-09-23&rft.volume=385&rft.issue=13&rft.spage=1207&rft.epage=1218&rft.pages=1207-1218&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMra1912719&rft_dat=%3Cproquest_cross%3E2575832036%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2575498806&rft_id=info:pmid/34551230&rfr_iscdi=true |